Literature DB >> 1193736

Murine model for study of cell-mediated immunity: protection against death from fully virulent Francisella tularensis infection.

H T Eigelsbach, D H Hunter, W A Janssen, H G Dangerfield, S G Rabinowitz.   

Abstract

To assess cell-mediated immunity in terms of host protection, an experimental model was developed in which passively transferred spleen cells from immunized AKR/J mice enabled nonimmume syngeneic recipients to survive an otherwise fatal infection with fully virulent Francisella tularensis. Donor immunization was achieved by administering live attenuted tularemia vaccine and, subsequently, the virulent streptomycin-sensitive SCHU S4 strain of F. tularensis. At selected intervals after immunization, donor spleen cells were transferred to streptomycin-treated recipients challenged subcutaneously, intravenously, or intraperitoneally with 25 to 50 minimal lethal doses of virulent streptomycin-resistant F. tularensis SCHU S5. The protection afforded by immune spleen cells was maximal (essentially 100%) 12 days after the SCHU S4 secondary immunization.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1193736      PMCID: PMC415388          DOI: 10.1128/iai.12.5.999-1005.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  An analysis of forty-two cases of laboratory-acquired tularemia. Treatment with broad spectrum antibiotics.

Authors:  E L OVERHOLT; W D TIGERTT; P J KADULL; M K WARD; N D CHARKES; R M RENE; T E SALZMAN; M STEPHENS
Journal:  Am J Med       Date:  1961-05       Impact factor: 4.965

Review 2.  Vaccines and cell-mediated immunity.

Authors:  F M Collins
Journal:  Bacteriol Rev       Date:  1974-12

3.  Resistance of inbred mice to Salmonella typhimurium.

Authors:  H G Robson; S I Vas
Journal:  J Infect Dis       Date:  1972-10       Impact factor: 5.226

4.  Recent studies on live tularemia vaccine.

Authors:  H T Eigelsbach; R B Hornick; J J Tulis
Journal:  Med Ann Dist Columbia       Date:  1967-05

5.  Antibiotic prophylaxis and therapy of airborne tularemia.

Authors:  W D Sawyer; H G Dangerfield; A L Hogge; D Crozier
Journal:  Bacteriol Rev       Date:  1966-09

6.  The effect of anti-lymphocyte globulin on cell-mediated reistance to infection.

Authors:  G B Mackaness; W C Hill
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

7.  The host response to Calmette-Guérin bacillus infection in mice.

Authors:  R V Blanden; M J Lefford; G B Mackaness
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

8.  The short lived small lymphocyte as a mediator of cellular immunity.

Authors:  D D McGregor; F T Koster; G B Mackaness
Journal:  Nature       Date:  1970-11-28       Impact factor: 49.962

9.  Early appearance of sensitized lymphocytes in mice infected with Listeria monocytogenes.

Authors:  R M Zinkernagel; R V Blanden; R E Langman
Journal:  J Immunol       Date:  1974-02       Impact factor: 5.422

10.  Immunogenicity of living and heat-killed Salmonella pullorum vaccines.

Authors:  F M Collins
Journal:  Infect Immun       Date:  1973-05       Impact factor: 3.441

View more
  16 in total

1.  Modulation of delayed-type hypersensitivity and cellular immunity to microbial vaccines: effects of cyclophosphamide on the immune response to tularemia vaccine.

Authors:  M S Ascher; D Parker; J L Turk
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

2.  Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs.

Authors:  Rebecca V Anderson; Deborah D Crane; Catharine M Bosio
Journal:  Vaccine       Date:  2010-08-03       Impact factor: 3.641

3.  Mouse models of aerosol-acquired tularemia caused by Francisella tularensis types A and B.

Authors:  David L Fritz; Marilyn J England; Lynda Miller; David M Waag
Journal:  Comp Med       Date:  2014-10       Impact factor: 0.982

4.  Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A.

Authors:  Terry H Wu; Julie A Hutt; Kristin A Garrison; Lyudmila S Berliba; Yan Zhou; C Rick Lyons
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

5.  CD4+ and CD8+ T-cell-dependent and -independent host defense mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice.

Authors:  J W Conlan; A Sjöstedt; R J North
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

6.  Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules.

Authors:  A H Fortier; T Polsinelli; S J Green; C A Nacy
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

7.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

8.  Respiratory tularemia: comparison of selected routes of vaccination in Fischer 344 rats.

Authors:  J V Jemski
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

9.  Glucan-induced enhancement of host resistance to selected infectious diseases.

Authors:  J A Reynolds; M D Kastello; D G Harrington; C L Crabbs; C J Peters; J V Jemski; G H Scott; N R Di Luzio
Journal:  Infect Immun       Date:  1980-10       Impact factor: 3.441

10.  Mechanisms of protective immunogenicity of microbial vaccines: effects of cyclophosphamide pretreatment in Venezuelan encephalitis, Q fever and tularaemia.

Authors:  M S Ascher; P B Jahrling; D G Harrington; R A Kishimoto; V G McGann
Journal:  Clin Exp Immunol       Date:  1980-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.